Ehlers-Danlos Syndrome

Ehlers-Danlos Syndrome (EDS) is a group of connective tissue disorders.

• Genetics: Multiple types with different genes. Most autosomal dominant.
• Prevalence: 1 in 5,000 (hEDS more common).
• Pathophysiology: Defects in collagen or proteins that interact with collagen.

Collagen Abnormalities

• Different types affect different collagen genes.
• Leads to weak ligaments, skin, blood vessels.

Why Joint Instability Occurs

• Ligaments are lax and cannot stabilize joints.
• Recurrent subluxations and dislocations.
• Chronic pain from microtrauma and joint damage.

The topic states repeatedly that hEDS is "diagnosed clinically" by the "2017 criteria," but the actual criteria deserve to be set out, because hEDS is the one subtype with no confirmatory gene — the diagnosis rests entirely on this framework. All three criteria must be met:

Patients with symptomatic hypermobility who do not satisfy all three are classified as hypermobility spectrum disorder (HSD) — which is managed identically.

Hypermobility Spectrum Disorders:

Key Distinguishing Points:

• EDS: Skin AND joint involvement, chronic pain
• Marfan: Cardiovascular focus, tall thin habitus
• OI: Bone fragility primary (fractures)
• Benign hypermobility: Hypermobility only, no pain syndrome

• Extended Immobilization: Tissues need longer to heal.
• Careful Suturing: Leave sutures longer.
• Physiotherapy: Gradual, cautious.

• hEDS: Normal lifespan but chronic symptoms.
• Vascular EDS: Reduced life expectancy (arterial rupture).
• Surgical Outcomes: Higher failure rate than general population.

The topic repeatedly cites "chronic pain and fatigue" and the controversies note that pain is driven by "central sensitisation and dysautonomia" — worth developing, because hEDS is a multisystem disorder, not just a joint problem, and this reframes management.

The comorbidity cluster. hEDS commonly co-occurs with a recognised triad of systemic problems:

• Dysautonomia / orthostatic intolerance — most characteristically postural orthostatic tachycardia syndrome (POTS), with light-headedness, palpitations, presyncope and fatigue on standing.
• Functional gastrointestinal disorders / dysmotility — reflux, bloating, early satiety and IBS-type symptoms.
• Mast cell activation symptoms — flushing, urticaria, and food or drug sensitivities.

Also frequent: chronic fatigue, anxiety and depression, pelvic-floor dysfunction with urogenital or rectal prolapse, and easy bruising.

Why the pain persists. Chronic pain in hEDS is not explained by joint laxity alone. It is increasingly understood as nociplastic pain with central sensitisation, compounded by dysautonomia, deconditioning and impaired proprioception — which is why pain frequently continues even when the joints are mechanically "stable," and why isolated stabilisation surgery rarely resolves it.

The orthopaedic take-home. Treat the orthopaedic complaint as one facet of a systemic disorder: prioritise graded, proprioceptive physiotherapy and pacing, multimodal and neuromodulatory analgesia, and management of the autonomic and GI comorbidities, within a multidisciplinary team — and always screen for the vascular-EDS red flags before any intervention.

Global epidemiology

• All EDS types combined: roughly 1 in 5,000. Hypermobile EDS / hypermobility spectrum disorders dominate (the large majority of cases).
• Vascular EDS is rare: 1 in 50,000 to 1 in 200,000 (Byers et al, 2017).
• hEDS shows a marked female predominance in clinic populations; rare recessive types (kyphoscoliotic, dermatosparaxis) cluster in consanguineous populations.

Side-by-side guidance

There is no orthopaedic implant registry signal specific to EDS, but registry-style cohort data (e.g. the Pepin NEJM cohort) underpin natural-history estimates, and the international EDS registry is building genotype-phenotype data.

High- vs limited-resource practice

• Well-resourced: gene-panel/exome testing, MDT (genetics, rheumatology, cardiology, physiotherapy, pain), celiprolol for vascular EDS, annual cross-sectional vascular imaging.
• Limited-resource: diagnosis remains largely clinical (Beighton score, skin and family history); prioritise physiotherapy, activity advice and recognition of vascular EDS red flags for urgent referral when genetic testing and celiprolol are unavailable.

• The hEDS / HSD boundary: hEDS still has no identified gene and is diagnosed by clinical criteria alone. The distinction from hypermobility spectrum disorder (HSD) is debated, and many "hEDS" patients meet HSD rather than strict 2017 criteria — management is the same.
• Paediatric diagnosis: A higher Beighton cut-off (the 2023 international paediatric framework proposes greater than or equal to 6/9) better identifies true hypermobility in children, and the label hEDS is reserved for biologically mature adolescents.
• Surgical decision-making: There is no high-level evidence on whether stabilisation procedures (e.g. shoulder, patellofemoral) durably outperform sustained rehabilitation in EDS; higher recurrence is consistently reported but optimal patient selection is unclear.
• Celiprolol generalisability: Benefit was shown mainly in COL3A1-confirmed and clinically diagnosed vascular EDS in a small trial; its value in mutation-negative phenotypes and in non-vascular subtypes is unproven.
• Pain mechanisms: Chronic pain in hEDS is increasingly attributed to central sensitisation and dysautonomia rather than joint laxity alone, shifting management toward multimodal and neuromodulatory approaches.